SOPHiA DDM™ uncovers cancer evolution under targeted therapies

Glad to continue my #ResearchSpotlight series with a study recently published in Nature Communications that puts the SOPHiA DDM™ platform at the center of new insights into how targeted therapies can reshape the evolution of #cancer.    In 143 patients with myeloproliferative neoplasms (MPN) analyzed on the SOPHiA DDM™ platform, the authors uncovered striking dynamics:    · Patients treated with the JAK2 inhibitor ruxolitinib accumulated more mutations, especially in the RAS pathway.  · These mutations correlated with worse outcomes under treatment.  · Lab experiments confirmed that JAK2 inhibition can select resistant clones.    The message is clear: cancer adapts, and therapies can drive that evolution in unexpected ways. For clinicians, it may mean that screening for RAS mutations becomes essential when treating MPN with JAK inhibitors. While ruxolitinib offers great benefits for a subset of patients, it may drive negative clinical outcomes in some other patients. This kind of longitudinal, real-world genomic insight is exactly what’s needed to stay ahead, and why we built our solutions at SOPHiA GENETICS: to help decode complexity so clinicians and researchers can adapt strategies and improve outcomes.     I’m particularly proud to see our platform supporting leading centers such as Gustave Roussy, and Hôpital Saint-Louis in Paris - where Dr. Bruno Cassinat and colleagues are advancing the study of myeloid disorders and contributing to this important progress.    Authored by Nabih Maslah, Nina Kaci, Blandine ROUX, Gabriela Alexe, Raphael Marie, Helene Pasquer, Emmanuelle VERGER, Rafael Daltro De Oliveira, Cécile Culeux, Bochra MLAYAH, Nicolas Gauthier, Fanny Gonzalez-de-Chavez, Lin-Pierre Zhao, Saravanan Ganesan, Panhong Gou, Frank Ling, Juliette Soret-DULPHY, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Rose Ann P., Stephane Giraudier, Caroline Marty, Isabelle Plo, Camille Lobry, Kimberly Stegmaier, Alexandre Puissant, Jean-Jacques Kiladjian, bruno cassinat & Lina Benajiba. Link to the full study: https://lnkd.in/eZ3GvB2U Springer Nature